However, since the same date, HZNP is down only 18%. Usually, stocks like HZNP should underperform the index since HZNP is one of the highlighted stock as price gouger that affected IBB in first place.
When PFE, JNJ, GILD and many other good stocks are at a deep discount, funds switch from riskier stocks to them. In this case, investors and funds rather have a more stable company like JNJ at discount than a more riskier stock like HZNP.
After all, HZNP volume is decreasing while its volatility is increasing. This is an activity that may bring more downside for the stock.
Based on some analysts, price gouging talks will stay around for while, at least for next few months and it will push IBB even lower than current prices. One way or another, HZNP will be affected but it may not be as lucky as these days. It may break down for much lower prices since investors will not be interested in risky stocks.
Unfortunately, there is not any help from other sectors too. Financial, energy and tech stocks are dealing with their own problems and they may put more pressure on IBB.
JNJ is down about 4%.
This market does not know anything about any stock except to sell and get more cash.
I never thought that GILD to go down this way after beating and raising the outlook significantly.
Besides recession and bad market, I heard that HZNP technical is weak and future recovery is very hard. I am afraid that we see much lower prices. So, what is left for me to do. I am reducing at any bounce.
He made his money by raising prices. But he was smart enough to not do it for ibuprofen.
We may not see it in some small cap stocks but big guys in the sector are shaking up.
Today, PFE with strong recommendation from many analysts dropped 2.25%. It was down over 3% after open. This was due to Shkreli.
Clinical stage-stage companies have the worst performance in 2016. Some are down over 50%.
Of course, FDA has a negative view on some of their drugs and that caused them to be punished.
Too much risk if a company, especially a small cap has a Phase III drug for approval. It seems that FDA is much tougher on small companies with not much experience in clinical study.
Brazil and many other countries besides gulf countries. Some like Azerbaijan have to borrow money.
Well, they say that some companies are paying unfairly taxes in the country that they do business.
With new law, if a company do business, say in France, then it has pas the same taxes for that portion of business. US will follow soon. So if HZNP makes $100m in US then it has to pay US taxes that other US companies are paying. No advantage to be out of USA. As a matter of fact, it will be a disadvantage.
Shirazi did not say that the stock goes to $11-$12. You are making up this corvette. However, I agree that HZNP technical is very weak and both bollinger bands and 50 DMA are trending down while HZNP is trading in lower band and some strong resistances have been forming above $19 recently. I say, between $16 and $20 for next few weeks depending on the market. If $16 breaks down then $13 is the support.
I was looking for some reasons that why biotech stocks that used to be darling of the market become so cheap that people are scared to touch them. So, one of the issue that everybody agrees on one point which high drug prices. From congress to candidates of both parties and also insurances, ES, CVS and almost most or all people complain about high drug prices. It is ok to increase some to compensate for higher expenses but 1500% or numbers like that are pure greed.
Some companies just waste money and then they want to compensate their waste with higher prices. How much did HZNP lose because it was insisting to acquire DEPO? Well the losses should be covered somehow.
Dow and other indexes will have lower lows. Dow low point for new trend was in mid 15,000 in August 2015. This time, we will see low 15,000. Worst case scenario will be high 14,000. Of course, Dow will go back and recover until next cycle which will be in Summer. Dow will see low 14,000 and high 13,0000. Eventually, the bottom will be reached at the end of the year around 12,000. Year 2017 will be the year that all stocks will recover.
Updated income for 2015 = $1.92 from $1.85 a week ago
Updated income for 2016 = $2.33 from $2.22 a week ago.
Keep raising and raising. When we will see reflection in the PPS?
How low one person can get. After all, he is wasting his time here and he needs to go to DEPO board and pump there to compensate for some of his losses.
Sentiment: Strong Buy
HZNP will get its true value eventually. HZNP Value will not be affected by some retail bashers.
Sentiment: Strong Buy
Duexis, Vimovo and Pennsaid 2% are drugs for arthritis. Well, Krystexxa is for chronic arthritis.
HZNP sale force can easily adopt this new drug and run with it.
Of course, there will be a limited patients but more patients will be identified every year. HZNP needs an average of $40m per quarter for 10 years out of this drug. Can HZNP make it? Of course it can and more.
Only around 4k patients have been treated so far. I think, HZNP will do well and get the most millage out of this drug and probably expands to other patient population in future.
I say this a small deal and the company is a private company. No shareholders disagreement. Most deals this size close fast and in average 45 days to 60 days. DEPO closed Nucynta deal in 2.5 months. End of January is in Q1, it is 50 days after announcement and it is quick enough for CEO to say "quickly".
Actually, this is not a subject that we should drag. Who cares if the deal closes in 50 days or 75 days, as long the deal closes in Q1 or before March 30 2016.
First of all, EBITDA is $45m to $50m but not $40m to $50. Why are you changing the numbers?
Second, the latest time is end of Jan (almost 45 days at max) but Crealta is not stopping the sale. The company is not changing the sales force either but adding more to it.
For 11 month of 2016, rev is $64m to $73m and EBITDA of $41.3m to $45.8m.
Thank you magic9z9. Crealta is not a public company for shareholders to approve the deal. The deal already was approved by both companies BODs. All the deal needs customary and regulatory waiting period which should not be any problem.
Injecting uncertainties is like basing indirectly. I thought sfvictim is good at it.
You say correct to geri, do you mean that TW was lying to us. In CC, TW repeated 2 times, at minute 5:48 and also minute 11:50 that this transaction will be completed in Q1, actually he emphasized "quickly" in Q1 and accretive "immediately" after close. In addition, the print says Q1 and slides say Q1 at 2 places.
Do you guys know better than the company and its CEO?